2021
DOI: 10.1016/j.ajog.2021.01.027
|View full text |Cite
|
Sign up to set email alerts
|

Professionally responsible coronavirus disease 2019 vaccination counseling of obstetrical and gynecologic patients

Abstract: The development of COVID-19 vaccines in current and planned clinical trials is essential for the success of this public health response. This paper focuses on how physicians should implement the results of these clinical trials: counseling patients who are pregnant, planning to become pregnant, breastfeeding or planning to breastfeed about vaccines with government authorization for clinical use. Determining the most effective approach to counseling patients about COVID-19 vaccination is challenging. We address… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

1
52
0
2

Year Published

2021
2021
2022
2022

Publication Types

Select...
9

Relationship

2
7

Authors

Journals

citations
Cited by 62 publications
(58 citation statements)
references
References 49 publications
1
52
0
2
Order By: Relevance
“…In the absence of trial data among pregnant women, guidance from governments and professional bodies is highly variable with respect to pregnancy and vaccination, and subject to change; many currently recommend an individual risk-benefit approach which is challenging given the evidence gap (46). The recent announcement of a Phase 2/3 study to assess the safety, tolerability, and immunogenicity of the Pfizer-BioNTech COVID-19 vaccine (BNT162b2) in preventing COVID-19 in healthy pregnant women is therefore very welcome (ClinicalTrials.gov Identifier: NCT04754594).…”
Section: Covid-19 Considerationsmentioning
confidence: 99%
“…In the absence of trial data among pregnant women, guidance from governments and professional bodies is highly variable with respect to pregnancy and vaccination, and subject to change; many currently recommend an individual risk-benefit approach which is challenging given the evidence gap (46). The recent announcement of a Phase 2/3 study to assess the safety, tolerability, and immunogenicity of the Pfizer-BioNTech COVID-19 vaccine (BNT162b2) in preventing COVID-19 in healthy pregnant women is therefore very welcome (ClinicalTrials.gov Identifier: NCT04754594).…”
Section: Covid-19 Considerationsmentioning
confidence: 99%
“…The coronavirus disease 2019 (COVID- 19) is a pandemic that has created a global health crisis that necessitated a public health response to limit all nidi of infection. South African data from 2020 demonstrated a 30% increase in maternal deaths since the pandemic started.…”
Section: Introductionmentioning
confidence: 99%
“…We thank Dr Habiba for his interest in our article. 1 Dr Habiba claims that our article failed to be "rooted in scientific rigor" because "vaccines have not been tested in pregnant women" in a randomized controlled clinical trial. In February 2021, Pfizer and BioNTech embarked on studying the effects of COVID-19 vaccination on pregnant women.…”
mentioning
confidence: 99%